Interacting with γ-secretase for treating Alzheimer's disease: From inhibition to modulation

Current Medicinal Chemistry

Volumn 18, Issue 35, 2011, Pages 5430-5447

  Panza, F ^a   Frisardi, V ^a   Solfrizzi, V ^b   Imbimbo, B P ^c   Logroscino, G ^b   Santamato, A ^d   Greco, A ^a   Seripa, D ^a   Pilotto, A ^a,e  

^a CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^b UNIVERSITY OF BARI   (Italy)

^c CHIESI FARMACEUTICI S P A   (Italy)

^d UNIVERSITY OF FOGGIA   (Italy)

^e S ANTONIO HOSPITAL   (Italy)

Author keywords

amyloid; secretase complex; secretase inhibitors; secretase modulators; Alzheimer's disease; Dementia; Mild cognitive impairment; Notch processing; Semagacestat; Tarenflurbil

Indexed keywords

AMYLOID BETA PROTEIN; ANTERIOR PHARYNX DEFECTIVE 1 PROTEIN; ASPARTIC PROTEINASE; AVAGACESTAT; BEGACESTAT; BMS 299897; BRAIN PROTEIN; CHF 5074; E 2012; E 2212; ELND 006; EVP 15962; GAMMA SECRETASE; GAMMA SECRETASE INHIBITOR; L 685458; MK 0752; N2 [2 (3,5 DIFLUOROPHENYL) 2 HYDROXYACETYL] N1 (6,7 DIHYDRO 5 METHYL 6 OXO 5H DIBENZ[B,D]AZEPIN 7 YL)ALANINAMIDE; NICASTRIN; NONSTEROID ANTIINFLAMMATORY AGENT; NOTCH RECEPTOR; NPG 328; PF 3084014; PLACEBO; PRESENILIN; PROTEIN PS2; SEMAGACESTAT; TARENFLURBIL; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; BREAST CARCINOMA; CARBOXY TERMINAL SEQUENCE; CELL FATE; CLINICAL TRIAL (TOPIC); COGNITIVE DEFECT; DEMENTIA; DIARRHEA; DRUG FATALITY; DRUG SUBSTITUTION; DRUG TARGETING; DRUG WITHDRAWAL; ENDOCARDITIS; HUMAN; INTESTINE OBSTRUCTION; LYMPHOCYTE DEPLETION; MILD COGNITIVE IMPAIRMENT; MULTICENTER STUDY (TOPIC); NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN CLEAVAGE; PROTEIN DEGRADATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; SINGLE DRUG DOSE; T CELL LEUKEMIA;

ALANINE; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; AZEPINES; ENZYME INHIBITORS; FLURBIPROFEN; HUMANS;

EID: 82255195306     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986711798194351     Document Type: Review

References (192)

1. Frisardi, V.; Solfrizzi, V.; Imbimbo, P. B.; Capurso, C.; D'Introno, A.; Colacicco, A. M.; Vendemiale, G.; Seripa, D.; Pilotto, A.; Capurso, A.; Panza, F. Towards disease-modifying treatment of Alzheimer's disease: drugs targeting beta-amyloid. Curr. Alzheimer Res., 2010, 7, 40-55.
2. Mangialasche, F.; Solomon, A.; Winblad, B.; Mecocci, P.; Kivipelto, M. Alzheimer's disease: clinical trials and drug development. Lancet Neurol, 2010, 9, 702-716.
3. Panza, F.; Solfrizzi, V.; Frisardi, V., Imbimbo, B. P, Capurso, C., D'Introno, A., Colacicco, A. M., Seripa, D., Vendemiale, G., Capurso, A., Pilotto, A. Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein. Aging Clin. Exp. Res., 2009, 21, 386-406.
4. Ferri, C. P.; Prince, M.; Brayne, C.; Brodaty, H.; Fratiglioni, L.; Ganguli, M.; Hall, K.; Hasegawa, K.; Hendrie, H.; Huang, Y.; Jorm, A.; Mathers, C.; Menezes, PR.; Rimmer, E.; Scazufca, M.; Alzheimer's Disease International. Global prevalence of dementia: a Delphi consensus study. Lancet, 2005, 366, 2112-2117. (Pubitemid 41797645)
5. Alzheimer's Association. Alzheimer's disease facts and figures. Alzheimers Dement, 2010, 6, 158-194.
6. Brookmeyer, R., Johnson, E., Ziegler-Graham, K., Arrighi, HM. Forecasting the global burden of Alzheimer's disease. Alzheimers Dement, 2007, 3, 186-191. (Pubitemid 46825511)
7. Seripa, D.; Panza, F.; Franceschi, M.; D' Onofrio, G.; Solfrizzi, V.; Dallapiccola, B.; Pilotto, A. Non-apolipoprotein E and apolipoprotein E genetics of sporadic Alzheimer's disease. Ageing Res. Rev., 2009, 8, 214-236.
8. Hardy, J.; Allsop, D. Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol. Sci., 1991, 12, 383-388.
9. Lesne, S.; Koh, M. T.; Kotilinek, L.; Kayed, R.; Glabe, C. G.; Yang, A.; Gallagher, M.; Ashe, K. H. A specific amyloid-P protein assembly in the brain impairs memory. Nature, 2006, 440, 352-357.
10. Shankar, G. M., Li, S., Mehta, T. H., Garcia-Munoz, A., Shepardson, N. E., Smith, I, Brett, F. M., Farrell, M. A., Rowan, M. J., Lemere, C. A., Regan, CM., Walsh, DM., Sabatini, B. L., Selkoe, D. J. Amyloid-P protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat. Med., 2008, 14, 837-842.
11. Barten, DM.; Albright, C. F. Therapeutic strategies for Alzheimer's disease. Mol. Neurobiol, 2008, 37, 171-186.
12. Ghosh, A. K.; Gemma, S. Tang J. beta-Secretase as a therapeutic target for Alzheimer's disease. Neurotherapeutics, 2008, 5, 399-408. (Pubitemid 351952491)
13. Imbimbo, B. P.; Giardina, G. A. γ-secretase inhibitors and modulators for the treatment of Alzheimer's disease: disappointments and hopes. Curr. Top Med. Chem., 2011, 11, 1555-1570.
14. Tomita, T. Secretase inhibitors and modulators for Alzheimer's disease treatment. Expert Rev. Neurother, 2009, 9, 661-679.
15. Panza, F.; Solfrizzi, V.; Frisardi, V.; Capurso, C.; D'Introno, A.: Colacicco, A. M.: Vendemiale, G.; Capurso, A.; Imbimbo, B. P. Disease-modifying approach to the treatment of Alzheimer's disease: from alpha-secretase activators to gamma-secretase inhibitors and modulators. Drugs Aging, 2009, 26, 537-555.
16. McCarthy, J. V; Twomey, C.; Wujek, P. Presenilin-dependent regulated intramembrane proteolysis and γ-secretase activity. Cell Mol. Life Sci., 2009, 66, 1534-1555.
17. Guardia-Laguarta, C.; Pera, M.; Lleó, A. γ-Secretase as a Therapeutic Target in Alzheimer's Disease. Curr. Drug Targets, 2010, 11, 506-517.
18. De Strooper, B.; Saftig, P.; Craessaerts, K.; Vanderstichele, H.; Guhde, G.; Annaert, W.; Von Figura, K.; Van Leuven F Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature, 1998, 391, 387-390. (Pubitemid 28093512)
19. Wolfe, M. S.; Xia, W.; Ostaszewski, B. L.; Diehl, T. S.; Kimberly, W. T.; Selkoe, D. J. Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and γ-secretase activity. Nature, 1999, 398, 513-517.
20. Yu, G.; Nishimura, M.; Arawaka, S.; Levitan, D.; Zhang, L.; Tandon, A.; Song, Y. Q.; Rogaeva, E.; Chen, F.; Kawarai, T.; Supala, A.; Levesque, L.; Yu, H.; Yang, D. S.; Holmes, E.; Milman, P.; Liang, Y.; Zhang, DM.; Xu, D. H.; Sato, C.; Rogaev, E., Smith, M.; Janus, C.; Zhang, Y.; Aebersold, R.; Farrer, L. S.; Sorbi, S.; Bruni, A.; Fraser, P.; St George-Hyslop, P. Nicastrin modulates presenilin-mediated notch/glp-1 signal transduction and PAPP processing. Nature, 2000, 407, 48-54.
21. Bentahir, M.; Nyabi, O.; Verhamme, J.; Tolia, A.; Horré, K.; Wiltfang, J.; Esselmann, H.; De Strooper, B. Presenilin clinical mutations can affect ysecretase activity by different mechanisms. J. Neurochem., 2006, 96, 732-742.
22. Lleo, A.; Berezovska, O.; Growdon, J. H.; Hyman, B. T. Clinical, pathological, and biochemical spectrum of Alzheimer disease associated with PS-1 mutations. Am. J. Geriatr. Psychiatry, 2004, 12, 146-156. (Pubitemid 38250298)
23. Panza, F.; Frisardi, V.; Imbimbo, B. P.; Capurso, C.; Logroscino, G.; Sancarlo, D.; Seripa, D.; Vendemiale, G.; Pilotto, A.; Solfrizzi, V REVIEW: γ-Secretase inhibitors for the treatment of Alzheimer's disease: The current state. C. N. S. Neurosci. Ther, 2010, 16, 272-284.
24. Lleo, A. Activity of γ-secretase on substrates other than APP Curr. Top Med. Chem., 2008, 8, 9-16. (Pubitemid 351791042)
25. Petit, A.; Bihel, F.; Alvès da Costa, C.; Pourquié, O.; Checler, F.; Kraus, J. L. New protease inhibitors prevent γ-secretase- mediated production of Abeta40/42 without affecting Notch cleavage. Nat. Cell Biol, 2001, 3, 507-511. (Pubitemid 32422088)
26. Weggen, S.; Eriksen, J. L.; Das, P.; Sagi, S. A.; Wang, R.; Pietrzik, C. U.; Findlay, K. A.; Smith, T. E.; Murphy, M. P.; Bulter, T.; Kang, D. E.; Marquez-Sterling, N.; Golde, T. E.; Koo, E. H. A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity. Nature, 2001, 414, 212-216. (Pubitemid 33051236)
27. Peretto, I.; La Porta, E. γ-Secretase modulation and its promise for Alzheimer's disease: a medicinal chemistry perspective. Curr. Top Med. Chem. 2008, 8, 38-46. (Pubitemid 351791045)
28. Panza, F.; Frisardi, V.; Imbimbo, B. P.; D'Onofrio, G.; Pietrarossa, G.; Seripa, D.; Pilotto, A.; Solfrizzi, V Bapineuzumab: anti-p-amyloid monoclonal antibodies for the treatment of Alzheimer's disease. Immunotherapy, 2010, 2, 767-782.
29. Borchelt, D. R.; Thinakaran, G.; Eckman, C. B.; Lee, M. K.; Davenport, F.; Ratovitsky, T.; Prada, CM.; Kim, G.; Seekins, S.; Yager, D.; Slunt, H. H.; Wang, R.; Seeger, M.; Levey, A. I.; Gandy, S. E.; Copeland, N. G.; Jenkins, N. A.; Price, D. L.; Younkin, S. G.; Sisodia, S. S. Familial Alzheimer's diseaselinked presenilin 1 variants elevate Abeta1-42/1-40 ratio in vitro and in vivo. Neuron, 1996, 17, 1005-1013. (Pubitemid 26424026)
30. Citron, M.; Westaway, D.; Xia, W.; Carlson, G.; Diehl, T.; Levesque, G.; Johnson-Wood, K.; Lee, M.; Seubert, P.; Davis, A.; Kholodenko, D.; Motter, R.; Sherrington, R.; Perry, B.; Yao, H.; Strome, R.; Lieberburg, I.; Rommens, J.; Kim, S.; Schenk, D.; Fraser, P.; St George Hyslop, P.; Selkoe, D. J. Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic mice. Nat. Med, 1997, 3, 67-72. (Pubitemid 27019143)
31. Tomita, T.; Maruyama, K.; Saido, T. C.; Kume, H.; Shinozaki, K.; Tokuhiro, S.; Capell, A.; Walter, J.; Grünberg, J.; Haass, C.; Iwatsubo, T.; Obata, K. The presenilin 2 mutation (N141I) linked to familial Alzheimer disease (Volga German families) increases the secretion of amyloid beta protein ending at the 42nd (or 43rd) residue. Proc. Natl. Acad. Sci. U. S. A., 1997, 94, 2025-2030. (Pubitemid 27113955)
32. Zhang, Z.; Nadeau, P.; Song, W.; Donoviel, D.; Yuan, M.; Bernstein, A.; Yankner, B. A. Presenilins are required for gamma-secretase cleavage of beta-APP and transmembrane cleavage of Notch-1. Nat. Cell. Biol, 2000, 2, 463-465.
33. Wolfe, M. S.; Kopan, R. Intramembrane proteolysis: theme and variations. Science, 2004, 305, 1119-1123. (Pubitemid 39100316)
34. Armogida, M., Petit, A., Vincent, B., Scarzello, S., da Costa, C. A., Checler, F. Endogenous β-amyloid production in presenilin deficient embryonic mouse fibroblasts. Nature Cell Biol, 2001, 3, 1030-1033. (Pubitemid 34428750)
35. Wilson, C. A.; Doms, R. W.; Zheng, H.; Lee, V. M. Presenilins are not required for Ab42 production in the early secretory pathway. Nature Neurosci., 2002, 5, 849-855. (Pubitemid 34976649)
36. Lai, M. T.; Crouthamel, M. C.; DiMuzio, J.; Pietrak, B. L.; Donoviel, D. B.; Bernstein, A.; Gardell, S. J.; Li, Y. M.; Hazuda, D. A presenilin- independent aspartyl protease prefers the gamma-42 site cleavage. J. Neurochem., 2006, 96, 118-125.
37. Yagishita, S.; Futai, E.; Ishiura, S. In vitro reconstitution of γ-secretase activity using yeast microsomes. Biochem. Biophys. Res. Commun., 2008, 377, 141-145.
38. Sevalle, J.; Ayral, E.; Hernandez, J. F.; Martinez, J.; Checler, F. Pharmacological evidences for DFK167-sensitive presenilin-independent ysecretase-like activity. J. Neurochem., 2009, 110, 275-283.
39. Dovey, H. F.; John, V.; Anderson, J. P.; Chen, L. Z.; de Saint Andrieu, P.; Fang, L. Y.; Freedman, S. B.; Folmer, B.; Goldbach, E.; Holsztynska, E. J.; Hu, K. L.; Johnson-Wood, K. L.; Kennedy, S. L.; Kholodenko, D.; Knops, J. E.; Latimer, L. H.; Lee, M.; Liao, Z.; Lieberburg, I. M.; Motter, R. N.; Mutter, L. C.; Nietz, J.; Quinn, K. P.; Sacchi, K. L.; Seubert, PA.; Shopp, G. M.; Thorsett, E. D.; Tung, J. S.; Wu, J., Yang, S.; Yin, C. T.; Schenk, D. B.; May, PC.; Altstiel, L. D.; Bender, M. H.; Boggs, L. N.; Britton, T. C.; Clemens, J. C.; Czilli, D. L.; Dieckman-McGinty, D. K.; Droste, J. J.; Fuson, K. S.; Gitter, B. D.; Hyslop, PA.; Johnstone, EM.; Li, W. Y.; Little, S. P.; Mabry, T. E.; Miller, F. D.; Audia, J. E. Functional γ-secretase inhibitors reduce β-amyloid peptide levels in brain. J. Neurochem., 2001, 76, 173-181. (Pubitemid 32044380)
40. Kreft, A. F.; Martone, R.; Porte, A. Recent advances in the identification of γ-secretase inhibitors to clinically test the Aβ oligomer hypothesis of Alzheimer's disease. J. Med. Chem., 2009, 52, 6169-6188.
41. Capell, A.; Grünberg, J.; Pesold, B.; Diehlmann, A.; Citron, M.; Nixon, R.; Beyreuther, K.; Selkoe, D. J.; Haass, C. The proteolytic fragments of the Alzheimer's disease-associated presenilin-1 form heterodimers and occur as a 100-150-kDa molecular mass complex. J. Biol. Chem., 1998, 273, 3205-3211. (Pubitemid 28109729)
42. Yu, G.; Chen, F.; Levesque, G.; Nishimura, M.; Zhang, D. M.; Levesque, L.; Rogaeva, E.; Xu, D.; Liang, Y.; Duthie, M.; St George-Hyslop, P. H.; Fraser, P. E. The presenilin 1 protein is a component of a high molecular weight intracellular complex that contains β-catenin. J. Biol. Chem., 1998, 273, 16470-16475. (Pubitemid 28311430)
43. Yu, G.; Nishimura, M.; Arawaka, S.; Levitan, D.; Zhang, L.; Tandon, A.; Song, Y. Q.; Rogaeva, E.; Chen, F.; Kawarai, T.; Supala, A.; Levesque, L.; Yu, H.; Yang, D. S.; Holmes, E.; Milman, P.; Liang, Y.; Zhang, D. M.; Xu, D. H.; Sato, C.; Rogaev, E.; Smith, M.; Janus, C.; Zhang, Y.; Aebersold, R.; Farrer, L. S.; Sorbi, S.; Bruni, A.; Fraser, P.; St George-Hyslop, P. Nicastrin modulates presenilin-mediated notch/glp-1 signal transduction and PAPP processing. Nature, 2000, 407, 48-54.
44. Edbauer, D.; Winkler, E.; Haass, C.; Steiner, H. Presenilin and nicastrin regulate each other and determine amyloid β-peptide production via complex formation. Proc. Natl. Acad. Sci. U. S. A., 2002, 99, 8666-8671. (Pubitemid 34693617)
45. Chavez-Gutierrez, L.; Tolia, A.; Maes, E.; Li, T.; Wong, PC.; de Strooper, B. Glu (332) in the Nicastrin ectodomain is essential for γ-secretase complex maturation but not for its activity. J. Biol. Chem., 2008, 283, 20096-105.
46. Shah, S.; Lee, S. F.; Tabuchi, K.; Hao, Y. H.; Yu, C.; LaPlant, Q.; Ball, H.; Dann, C. E. 3r.; Südhof, T.; Yu, G. Nicastrin functions as a γ-secretasesubstrate receptor. Cell, 2005, 122, 435-447.
47. Crystal, A. S.; Morais, V. A.; Pierson, T. C.; Pijak, D. S.; Carlin, D.; Lee, V. M.; Doms, R. W. Membrane topology of γ-secretase component PEN-2. J. Biol. Chem., 2003, 278, 20117-20123. (Pubitemid 36799206)
48. Francis, R., McGrath, G., Zhang, J., Ruddy, D. A., Sym, M., Apfeld, J., Nicoll, M., Maxwell, M., Hai, B., Ellis, M. C., Parks, A. L., Xu, W., Li, J., Gurney, M., Myers, R. L., Himes, C. S., Hiebsch, R., Ruble, C., Nye, J. S., Curtis, D. Aph-1 and pen-2 are required for Notch pathway signaling, ysecretase cleavage of PAPP, and presenilin protein accumulation. Dev. Cell, 2002, 3, 85-97. (Pubitemid 34778398)
49. Niimura, M.; Isoo, N.; Takasugi, N.; Tsuruoka, M.; Ui-Tei, K.; Saigo, K.; Morohashi, Y.; Tomita, T.; Iwatsubo, T. Aph-1 contributes to the stabilization and trafficking of the gamma-secretase complex through mechanisms involving intermolecular and intramolecular interactions. J. Biol. Chem., 2005, 280, 12967-12975.
50. Serneels, L.; Van Biervliet, J.; Craessaerts, K.; Dejaegere, T.; Horré, K.; Van Houtvin, T.; Esselmann, H.; Paul, S.; Schäfer, M. K.; Berezovska, O.; Hyman, B. T.; Sprangers, B.; Sciot, R.; Moons, L.; Jucker, M.; Yang, Z.; May, PC.; Karran, E.; Wiltfang, J.; D'Hooge, R.; De Strooper, B. γ-Secretase heterogeneity in the Aph1 subunit: relevance for Alzheimer's disease. Science, 2009, 324, 639-642.
51. Shirotani, K.; Edbauer, D.; Prokop, S.; Haass, C.; Steiner, H. Identification of distinct γ-secretase complexes with different APH-1 variants. J. Biol. Chem., 2004, 279, 41340-41345. (Pubitemid 39313572)
52. Hébert, S. S.; Serneels, L.; Dejaegere, T.; Horré, K.; Dabrowski, M.; Baert, V.; Annaert, W.; Hartmann, D.; De Strooper, B. Coordinated and widespread expression of γ-secretase in vivo: evidence for size and molecular heterogeneity. Neurobiol. Dis., 2004, 17, 260-272. (Pubitemid 39345781)
53. Ma, G.; Li, T.; Price, D. L.; Wong, PC APH-1α is the principal mammalian APH-1 isoform present in γ-secretase complexes during embryonic development. J. Neurosci., 2005, 25, 192-198. (Pubitemid 40110780)
54. Serneels, L.; Dejaegere, T.; Craessaerts, K.; Horré, K.; Jorissen, E.; Tousseyn, T.; Hébert, S.; Coolen, M.; Martens, G.; Zwijsen, A.; Annaert, W.; Hartmann, D.; De Strooper, B. Differential contribution of the three Aph1 genes to γ-secretase activity in vivo. Proc. Natl. Acad. Sci. U. S. A., 2005, 102, 1719-1724. (Pubitemid 40209234)
55. Lai, M. T.; Chen, E.; Crouthamel, M. C.; DiMuzio-Mower, J.; Xu, M.; Huang, Q.; Price, E.; Register, R. B.; Shi, X. P.; Donoviel, D. B.; Bernstein, A.; Hazuda, D.; Gardell, S. J.; Li, YM. Presenilin-1 and presenilin-2 exhibit distinct yet overlapping γ-secretase activities. J. Biol. Chem., 2003, 278, 22475-22481. (Pubitemid 36830301)
56. Dejaegere, T.; Serneels, L.; Schafer, M. K.; Van Biervliet, J.; Horré, K.; Depboylu, C.; Alvarez-Fischer, D.; Herreman, A.; Willem, M.; Haass, C.; Höglinger, G. U.; D'Hooge, R.; De Strooper, B. Deficiency of Aph1B/C-γ-secretase disturbs Nrg1 cleavage and sensorimotor gating that can be reversed with antipsychotic treatment. Proc. Natl. Acad. Sci. U. S. A., 2008, 105, 9775-9780. (Pubitemid 352031376)
57. Shirotani, K.; Tomioka, M.; Kremmer, E.; Haass, C., Steiner, H. Pathological activity of familial Alzheimer's disease-associated mutant presenilin can be executed by six different γ-secretase complexes. Neurobiol. Dis., 2007, 27, 102-107. (Pubitemid 46921480)
58. Gu, Y.; Chen, F.; Sanjo, N.; Kawarai, T.; Hasegawa, H.; Duthie, M.; Li, W.; Ruan, X.; Luthra, A.; Mount, H. T.; Tandon, A.; Fraser, P. E.; St George-Hyslop, P. APH-1 interacts with mature and immature forms of presenilins and nicastrin and may play a role in maturation of presenilin. nicastrin complexes. J. Biol. Chem., 2003, 278, 7374-7380. (Pubitemid 36800741)
59. Prokop, S.; Shirotani, K.; Edbauer, D.; Haass, C.; Steiner, H. Requirement of PEN-2 for stabilization of the presenilin N-/Cterminal fragment heterodimer within the γ-secretase complex. J. Biol. Chem., 2004, 279, 23255-23261. (Pubitemid 38685633)
60. Kim, S. H.; Sisodia, S. S. A sequence within the first transmembrane domain of PEN-2 is critical for PEN-2-mediated endoproteolysis of presenilin 1. J. Biol. Chem., 2005, 280, 1992-2001.
61. Sato, T.; Diehl, T. S.; Narayanan, S.; Funamoto, S.; Ihara, Y.; De Strooper, B.; Steiner, H.; Haass, C.; Wolfe, M. S. Active γ-secretase complexes contain only one of each component. J. Biol. Chem., 2007, 282, 33985-33993. (Pubitemid 350159441)
62. Lazarov, V. K.; Fraering, PC.; Ye, W.; Wolfe, M. S.; Selkoe, D. J.; Li, H. Electron microscopic structure of purified, active γ-secretase reveals an aqueous intramembrane chamber and two pores. Proc. Natl. Acad. Sci. U. S. A., 2006, 103, 6889-6894.
63. Ogura, T.; Mio, K.; Hayashi, I.; Miyashita, H.; Fukuda, R.; Kopan, R.; Kodama, T.; Hamakubo, T.; Iwatsubo, T.; Tomita, T.; Sato, C. Three-dimensional structure of the γ-secretase complex. Biochem. Biophys. Res. Commun., 2006, 343, 525-534.
64. Osenkowski, P.; Li, H.; Ye, W.; Li, D.; Aeschbach, L.; Fraering, PC.; Wolfe, M. S.; Selkoe, D. J.; Li, H. Cryoelectron microscopy structure of purified γ-secretase at 12 Å resolution. J. Mol. Biol., 2009, 385, 642-652.
65. De Strooper, B.; Annaert, W.; Cupers, P.; Saftig, P.; Craessaerts, K.; Mumm, J. S.; Schroeter, E. H.; Schrijvers, V.; Wolfe, M. S.; Ray, W. J.; Goate, A.; Kopan, R. A presenilin-1-dependent γ-secretase-like protease mediates release of Notch intracellular domain. Nature, 1999, 398, 518-522.
66. Sestan, N, Artavanis-Tsakonas, S., Rakic, P. Contact-dependent inhibition of cortical neurite growth mediated by notch signaling. Science, 1999, 286, 741-746.
67. Marambaud, P.; Wen, PH.; Dutt, A.; Shioi, J.; Takashima, A.; Siman, R.; Robakis, N. K. A CBP binding transcriptional repressor produced by the PS1/y-cleavage of Ncadherin is inhibited by PS1 FAD mutations. Cell, 2003, 114, 635-645. (Pubitemid 37159259)
68. Ni, C. Y.; Murphy, M. P.; Golde, T. E.; Carpenter, G. γ-Secretase cleavage and nuclear localization of ErbB-4 receptor tyrosine kinase. Science, 2001, 294, 2179-2181. (Pubitemid 33150677)
69. Müller, T.; Meyer, H. E.; Egensperger, R.; Marcus, K. The amyloid precursor protein intracellular domain (AICD) as modulator of gene expression, apoptosis, and cytoskeletal dynamics-relevance for Alzheimer's disease. Prog. Neurobiol, 2008, 85, 393-406.
70. Wong, G. T.; Manfra, D.; Poulet, F. M.; Zhang, Q.; Josien, H.; Bara, T.; Engstrom, L.; Pinzon-Ortiz, M.; Fine, J. S.; Lee, H. J.; Zhang, L.; Higgins, G. A.; Parker, EM. Chronic treatment with the γ-secretase inhibitor LY-411, 575 inhibits β-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J. Biol. Chem., 2004, 279, 2876-2882.
71. Milano, J.; McKay, J.; Dagenais, C.; Foster-Brown, L.; Pognan, F.; Gadient, R.; Jacobs, R. T.; Zacco, A.; Greenberg, B.; Ciaccio, P. J. Modulation of notch processing by γ-secretase inhibitors causes intestinal goblet cell metaplasia and induction of genes known to specify gut secretory lineage differentiation. Toxicol. Sci., 2004, 82, 341-358. (Pubitemid 39485346)
72. Olson, R. E.; Albright, C. F. Recent progress in the medicinal chemistry of γ-secretase inhibitors. Curr. Top Med. Chem., 2008, 8, 17-33. (Pubitemid 351791043)
73. Li, Y. M.; Xu, M.; Lai, M. T.; Huang, Q.; Castro, J. L.; DiMuzio-Mower, J.; Harrison, T.; Lellis, C.; Nadin, A.; Neduvelil, J. G.; Register, R. B.; Sardana, M. K.; Shearman, M. S.; Smith, A. L.; Shi, X. P.; Yin, K. C.; Shafer, J. A.: Gardell, S. J. Photo activated γ-secretase inhibitors directed to the active site covalently label presenilin 1. Nature, 2000, 405, 689-694. (Pubitemid 30428655)
74. Esler, W. P.; Kimberly, W. T.; Ostaszewski, B. L.; Diehl, T. S.; Moore, C. L.; Tsai, J. Y.; Rahmati, T.; Xia, W.; Selkoe, D. J.; Wolfe, M. S. Transition-state analogue inhibitors of γ-secretase bind directly to presenilin-1. Nat. Cell Biol, 2000, 2, 428-434.
75. Lewis, H. D.; Pérez Revuelta, B. I.; Nadin, A.; Neduvelil, J. G.; Harrison, T.; Pollack, S. J.; Shearman, M. S. Catalytic sitedirected γ-secretase complex inhibitors do not discriminate pharmacologically between Notch S3 and β-APP cleavages. Biochemistry, 2003, 42, 7580-7586. (Pubitemid 36735835)
76. Comery, T. A.; Martone, R. L.; Aschmies, S.; Atchison, K. P.; Diamantidis, G.; Gong, X.; Zhou, H.; Kreft, A. F.; Pangalos, M. N.; Sonnenberg-Reines, J.; Jacobsen, J. S.; Marquis, K. L. Acute γ-secretase inhibition improves contextual fear conditioning in the Tg2576 mouse model of Alzheimer's disease. J. Neurosci., 2005, 25, 8898-8902. (Pubitemid 41384457)
77. Imbimbo, B. P Alzheimer's disease: γ-Secretase inhibitors. Drug Disc. Today-Ther. Strategies, 2008, 5, 169-175.
78. Best, J. D.; Jay, M. T.; Out, F.; Ma, J.; Nadin, A.; Ellis, S.; Lewis, H. D.; Pattison, C.; Reilly, M.; Harrison, T.; Shearman, M. S.; Williamson, T. L.; Atack, J. R. Quantitative measurement of changes in amyloid-P (40) in the rat brain and cerebrospinal fluid following treatment with the γ-secretase inhibitor LY-411575 [N2-[(2S)-2-(3, 5-difluorophenyl)-2-hydroxyethanoyl]-N1- [(7S)-5-methyl-6-oxo-6, 7-dihydro-5H-dibenzo[b, d]azepin-7-yl]-L-alaninamide]. J. Pharmacol. Exp. Ther, 2005, 313, 902-908. (Pubitemid 40604194)
79. Gitter, B. D.; Czilli, D. L.; Li, W.; Dieckman, D. K.; Bender, M. H.; Nissen, J. S.; Mabry, T. E.; Yin, T.; Boggs, L. N; McClure, D. B.; Little, S. P.; Johnstone, E. M.; Audia, J. E.; May, P. C., Hyslop, P. A. Stereoselective inhibition of amyloid β peptide secretion by LY450139 dihydrate, a novel functional gamma secretase inhibitor. Neurobiol. Aging, 2004, 25(Suppl. 2), S571 (Abstract P4-339).
80. Boggs, L. N; Fxuson, S. F.; Gitter, B. D.; Czilli, D. L.; Hyslop, P. A.; Bender, M. H.; Li, W.; Audia, J. E.; Nissen, J. S.; Mabry, T. E.; Ni, B.; May, P. C. In vivo characterization of LY450139, a novel, stereoselective, functional ysecretase inhibitor. Neurobiol. Aging, 2004, 25(Suppl. 2), S 218 (Abstract P1-419).
81. May, P. C.; Yang, Z.; Li, W.; Hyslop, P. A.; Siemers, E.; Boggs, L. N. Multicompartmental pharmacodynamic assessment of the functional γ-secretase inhibitor LY450139 in PDAPP transgenic mice and non-transgenic mice. Neuobiol. Aging, 2004, 25(Suppl. 25), 65 (Abstract O3-06-07).
82. Lanz, T. A.; Karmilowicz, M. J.; Wood, KM.; Pozdnyakov, N.; Du, P.; Piotrowski, M. A.; Brown, T. M.; Nolan, C. E.; Richter, K. E.; Finley, J. E.; Fei, Q.; Ebbinghaus, C. F.; Chen, Y. L.; Spracklin, D. K.; Tate, B.; Geoghegan, K. F.; Lau, L. F.; Auperin, D. D. Concentration-dependent modulation of Aβ in vivo and in vitro using the γ-secretase inhibitor, LY-450139. J. Pharmacol. Exp. Ther, 2006, 319, 924-933.
83. Cocke, P. J.; Boggs, L. N.; Ness, D. K.; May, P. C. Comparison of cisternal and lumbar cerebrospinal fluid amyloid beta concentrations following oral administration of LY450139 dihydrate to Beagle dogs. Alzheimers Dement, 2008, 4(Suppl 2), T210 (Abstract P1-017).
84. Ness, D. K.; Boggs, L. N.; Hepburn, D. L.; Gitter, B.; Long, G. G.; May, P. C.; Piroozi, K. S.; Schafer, K. A., Yang, Z. Reduced β-amyloid burden, increased C-99 concentrations and evaluation of neuropathology in the brains of PDAPP mice given LY450139 dihydrate daily by gavage for 5 months. Neurobiol. Aging, 2004, 25(Suppl. 2), S238 (Abstract P2-053).
85. Imbimbo, B. P.; Peretto, I. Semagacestat, a γ-secretase inhibitor for the potential treatment of Alzheimer's disease. Curr. Opin. Investig. Drugs, 2009, 10, 721-30.
86. Bittner, T.; Fuhrmann, M.; Burgold, S.; Jung, C. K.; Volbracht, C.; Steiner, H.; Mitteregger, G.; Kretzschmar, H. A.; Haass, C.; Herms, J. γ-Secretase inhibition reduces spine density in vivo via an amyloid precursor proteindependent pathway. J. Neurosci., 2009, 29, 10405-10409.
87. Siemers, E. R.; Dean, R. A.; Friedrich, S.; Ferguson-Sells, L.; Gonzales, C.; Farlow, M. R.; May, PC. Safety, tolerability, and effects on plasma and cerebrospinal fluid amyloid-beta after inhibition of γ-secretase. Clin. Neuropharmacol, 2007, 30, 317-325. (Pubitemid 350307310)
88. Siemers, E.; Skinner, M.; Dean, R. A.; Gonzales, C.; Satterwhite, J.; Farlow, M.; Ness, D.; May, PC. Safety, tolerability, and changes in amyloid beta concentrations after administration of a γ-secretase inhibitor in volunteers. Clin. Neuropharmacol, 2005, 28, 126-132. (Pubitemid 40923411)
89. Siemers, E. R.; Quinn, J. F.; Kaye, J.; Farlow, M. R.; Porsteinsson, A.; Tariot, P.; Zoulnouni, P.; Galvin, J. E.; Holtzman, DM.; Knopman, D. S.; Satterwhite, J.; Gonzales, C.; Dean, R. A.; May, PC. Effects of a γ-secretase inhibitor in a randomized study of patients with Alzheimer disease. Neurology, 2006, 66, 602-604. (Pubitemid 43739900)
90. Fleisher, A. S.; Raman, R.; Siemers, E. R.; Becerra, L.; Clark, CM.; Dean, R. A.; Farlow, M. R.; Galvin, J. E.; Peskind, E. R.; Quinn, J. F.; Sherzai, A.; Sowell, B. B.; Aisen, PS.; Thal, L. J. Phase 2 safety trial targeting amyloid beta production with a γ-secretase inhibitor in Alzheimer disease. Arch. Neurol, 2008, 65, 1031-1038.
91. Bateman, R. J.; Siemers, E. R.; Mawuenyega, K. G.; Wen, G.; Browning, K. R.; Sigurdson, W. C.; Yarasheski, K. E.; Friedrich, S. W.; Demattos, R. B.; May, PC.; Paul, S. M.; Holtzman, DM. A γ-secretase inhibitor decreases amyloid-P production in the central nervous system. Ann. Neurol, 2009, 66, 48-54.
92. ClinicalTrial.gov Effect of LY450139 on the Long Term Progression of Alzheimer's Disease [last accessed September 20, 2011: http://clinicaltrials. gov/ct2/show/NCT00594568?term=NCT00594568&rank=1].
93. ClinicalTrial.gov Effects of LY450139, on the Progression of Alzheimer's Disease as Compared With Placebo (IDENTITY-2) [last accessed September 20, 2011: http://clinicaltrials.gov/ct2/show/NCT00762411?term=IDENTITY&rank=9].
94. ClinicalTrial.gov A Study in Semagacestat for Alzheimer's Patients (Identity XT) [last accessed September 20, 2011: http://clinicaltrials.gov/ct2/ show/NCT01035138?term=IDENTITY&rank=8].
95. Siemers, E. Evaluating semagacestat, a gamma-secretase inhibitor, in a Phase III trial. Alzheimer's Association International Conference 2011. Paris, July 16-21, 2011.
96. [96 97] Ross, J. S.; Imbimbo, B. P. Are γ-secretase inhibitors detrimental for Alzheimer's disease patients? J. Alzheimers Dis., 2010, 22, 401-404
97. Morimoto B. Drug Development for Neurodegenerative Diseases - a Marcus Evans Conference. IDdb Meeting Report. Boston, MA, April 7-8, 2009.
98. Rosen, L. B.; Stone, J. A.; Plump, A.; Yuan, J.; Harrison, T.; Flynn, M.; Dallob, A.; Matthews, C.; Stevenson, D.; Schmidt, D.; Palmieri, T.; Leibowitz, M.; Jhee, S.; Ereshefsky, L.; Salomon, R.; Winchell, G.; Shearman, M. S.; Murphy, M. G.; Gottesdiener, K. M. The γ-secretase inhibitor MK-0752 acutely and significantly reduces CSF Aβ40 concentrations in humans. Alzheimers Dement, 2006, 2(Suppl 1), S79 (Abstract O4-03-02).
99. Deangelo, D. J.; Stone, R. M.; Silverman, L. B.; Stock, W.; Attar, E. C.; Fearen, I.; Dallob, A.; Matthews, C.; Stone, J.; Freedman, S. J.; Aster, J. A phase I clinical trial of the notch inhibitor MK-0752 in patients with T-cell acute lymphoblastic leukemia/lymphoma (T-ALL) and other leukemias. J. Clin. Oncol. 2006, 24(Suppl 18), 6585.
100. Krop, I. E.; Kosh, M.; Fearen, I.; Savoie, J.; Dallob, A.; Matthews, C.; Stone, J.; Winer, E.; Freedman, S. J.; Lorusso, P. Phase I pharmacokinetic (PK), and pharmacodynamic (PD) trial of the novel oral Notch inhibitor MK-0752 in patients (pts) with advanced breast cancer (BC) and other solid tumors. J. Clin. Oncol, 2006, 24(Suppl 18), 10574.
101. Gillman, K. W.; Starrett, J. E.; Parker, M. F.; Xie, K.; Bronson, J. J.; Marcin, L. R.; McElhone, K. E.; Bergstrom, C. P.; Mate, R. A.; Williams, R.; Meredith, J. E. Jr.; Burton, C. R.; Barten, DM.; Toyn, J. H.; Roberts, S. B.; Lentz, K. A.; Houston, J. G.; Zaczek, R.; Albright, C. F.; Decicco, C. P.; Macor, J. E.; Olson, R. E. Discovery and evaluation of BMS-708163, a potent, selective and orally bioavailable γ-secretase inhibitor. A. C. S. Med. Chem. Lett, 2010, 1, 120-124.
102. th International Conference on Alzheimer's Disease (ICAD), 26-31 July 2008, Chicago, IL, USA (Abstract HT-01-05).
103. Tong, G.; Castaneda, L.; Wang, J. S.; Sverdlov, A.; Huamg, S.; Slemmon, R.; Gu, H.; Wong, O.; Li, H.; Berman, R. M.; Smith, C.; Albright, C. F. A study to evaluate the effects of single oral doses of BMS-708163 in the cerebrospinal fluid of healthy young men. Alzheimers Dement, 2010;6(Suppl 1), S143 (Abstract O3-07-07).
104. Wang, J. S.; Castaneda, L.; Sverdlov, A.; Huang, S. P.; Slemmon, R.; Gu, H.; Wong, O.; Li, H.; Berman, R. M.; Smith, C.; Albright, C. F A placebocontrolled, ascending, multiple-dose study to evaluate the safety, pharmacokinetics (P) and pharmacodynamics (PD) of BMS-708163 in healthy young and elderly subjects. Alzheimers Dement, 2010, 6(Suppl 1), S540 (Abstract P3-303).
105. ClinicalTrial.gov A Phase II, Multicenter, Double Blind, Placebo-Controlled Safety, Tolerability Study of BMS-708163 in Patients With Mild to Moderate Alzheimer's Disease [last accessed September 20, 2011: http://clinic altrials.gov/ct2/show/NCT00810147?term=NCT00810147&rank=1].
106. ClinicalTrial.gov A Multicenter, Double Blind, Placebo-Controlled, Safety and Tolerability Study of BMS-708163 in Patients With Prodromal Alzheimer's Disease [last accessed September 20, 2011: http://clinicaltrials.gov/ct2/show/ NCT00890890].
107. Lanz, T. A.; Wood, KM.; Richter, K. E.; Nolan, C. E.; Becker, S. L.; Pozdnyakov, N.; Martin, B. A.; Du, P.; Oborski, C. E.; Wood, D. E.; Brown, TM.; Finley, J. E.; Sokolowski, S. A.; Hicks, CD.; Coffman, K. J.; Geoghegan, K. F.; Brodney, M. A.; Liston, D.; Tate, B. Pharmacodynamics and pharmacokinetics of the γ-secretase inhibitor PF-3084014. J. Pharmacol. Exp. Ther, 2010, 334, 269-77.
108. Brodney, M. Discovery of PF-3084014: A novel γ-secretase inhibitor for the treatment of Alzheimer's disease. 238th ACS National Meeting, Washington, DC., August 16-20, 2009 (Abstract MEDI 233).
109. Qui, R.; Willavize, S.; Fullerion, T.; Gastonguay, M. R. Modeling and simulation of plasma Aβ in humans after multiple oral doses of Pf-3084014, a potent γ-secretase inhibitor. Alzheimers Dement, 2009;5(Suppl 1), P253 (Abstract P1-261).
110. ClinicalTrial.gov A Trial In Patients With Advanced Cancer And Leukemia [last accessed September 20, 2011: ttp://clinicaltrials.gov/ct2/show/ NCT00878189?term=NCT00878189&rank=1].
111. Martone, R. L.; Zhou, H.; Atchison, K.; Comery, T.; Xu, J. Z.; Huang, X.; Gong, X.; Jin, M.; Kreft, A.; Harrison, B.; Mayer, S. C.; Aschmies, S.; Gonzales, C.; Zaleska, MM.; Riddell, D. R.; Wagner, E.; Lu, P.; Sun, S. C.; Sonnenberg-Reines, J.; Oganesian, A.; Adkins, K.; Leach, M. W.; Clarke, D. W.;
112. Frick, G.; Raje, S.; Wan, H.; Forlow; S. B.; Balliet, C.; Pastore, A.; Burczynski, M. E.; Jhee, S.; Ereshefsky, L.; Paul, J. GSI-953, a potent and selective γ-secretase inhibitor - Modulation of β amyloid peptides and plasma and cerebrospinal fluid pharmacokinetic/pharmacodynamic relationships in humans. Alzheimers Dement, 2008, 4(Suppl. 2), T781 (Abstract P4-366).
113. Wan, H.; Bard, J.; Martone, R.; Rage, S.; Forlow, S.; Kreft, A.; Jacobsen, S.; Silver, P.; Paul, J.; Frick, G. GSI-953, a potent and selective γ-secretase inhibitor, modulates Aβ peptides in mice and humans: Translating the PK/PD biomarker relationships in different biological compartments between rodent and human. Alzheimers Dement, 008, 4(Suppl. 2), T548 (Abstract P2-101).
114. Brigham, E.; Quinn, K.; Kwong, G.; Willits, C.; Goldbach, E.; Motter, R.; Lee, M.; Wallace, W.; Kholodenko, D.; Tang-Tanake, P.; Ni, H.; Hemphill, S.; Chen, X. H.; Eichenbaum, T.; Ruslim, L.; Nguyen, L.; Santiago, P.; Liao, A.; Bova, M.; Probst, G.; Dappen, M.; Jagodzinski, J.; Basi, G.; Ness, D. Pharmacokinetic and pharmacodynamic investigation of ELND006, a novel APP-selective γ-secretase inhibitor, on amyloid-P concentrations in the brain, CSF and plasma of multiple nonclinical species following oral administration.. Alzheimers Dement, 2010a, 6(Suppl 1), S546 (Abstract P3-320).
115. Brigham, E.; Quinn, K.; Motter, R.; Hoffman, W.; Goldbach, E.; Kholodenko, D.; Kwong, G.; Willits, C.; Probst, G.; Gunther, J.; Admas, E.; Sauer, J. M.; Kinney, G.; Ness, D. Effects of single and multiple dose oral administration of ELND006, a novel APP-selective γ-secretase inhibitor, on amyloid-P concentrations in the brain and CSF of cynomolgus monkeys. Alzheimers Dement, 2010b, 6(Suppl 1), S546 (Abstract P3-322).
116. Schroeter, A.; Brigham, E.; Motter, R.; Nishioka, C.; Guido, T.; Khan, K.; Kholodenko, D.; Tanaka, P.; Soriano, F.; Quinn, K.; Goldbach, E.; Games, D.; Ness, D. APP-selective γ-secretase inhibitor ELND006 effects on brain parenchymal and vascular amyloid-P in the PDAPP mouse model of Alzheimer's disease. Alzheimers Dement, 2010;6(Suppl 1):S546 (Abstract P3-321).
117. Sagi, S. A.; Weggen, S.; Eriksen, J.; Golde, T. E., Koo, E. H. The noncyclooxygenase targets of non-steroidal anti-inflammatory drugs, lipoxygenases, peroxisome proliferator-activated receptor, inhibitor of κB kinase, and NFkB, do not reduce amyloid-P 42 production. J. Biol. Chem., 2003, 278, 31825-31830. (Pubitemid 37048364)
118. Eriksen, J. L.; Sagi, S. A.; Smith, T. E.; Weggen, S.; Das, P.; McLendon, D. C.; Ozols, V. V.; Jessing, K. W.; Zavitz, K. H.; Koo, E. H.; Golde, T. E. NSAIDs and enantiomers of flurbiprofen target γ-secretase and lower Aβ42 in vivo. J. Clin. Invest, 2003, 112, 440-449. (Pubitemid 38063773)
119. 1-42 secretion. J. Med. Chem., 2005, 48, 5705-5720. (Pubitemid 41298345)
120. Lleó, A.; Berezovska, O.; Herl, L.; Raju, S.; Deng, A.; Bacskai, B. J.; Frosch, M. P.; Irizarry, M.; Hyman, B. T. Nonsteroidal anti-inflammatory drugs lower Abeta42 and change presenilin 1 conformation. Nat. Med., 2004, 10, 1065-1066. (Pubitemid 39424866)
121. Takahashi, Y.; Hayashi, I.; Tominari, Y.; Rikimaru, K.; Morohashi, Y.; Kan, T.; Natsugari, H.; Fukuyama, T.; Tomita, T.; Iwatsubo, T. Sulindac sulfide is a noncompetitive gamma-secretase inhibitor that preferentially reduces Abeta 42 generation. J. Biol. Chem., 2003, 278, 18664-18670. (Pubitemid 36799494)
122. Kukar, T.; Murphy, M. P.; Eriksen, J. L.; Sagi, S. A.; Weggen, S.; Smith, T. E.; Ladd, T.; Khan, M. A.; Kache, R.; Beard, J.; Dodson, M.; Merit, S.; Ozols, V. V.; Anastasiadis, P. Z.; Das, P.; Fauq, A.; Koo, E. H.; Golde, T. E. Diverse compounds mimic Alzheimer disease-causing mutations by augmenting Abeta42 production. Nat. Med., 2005, 11, 545-350.
123. Czech, C.; Burns, M. P.; Vardanian, L.; Augustin, A.; Jacobsen, H.; Baumann, K.; Rebeck, G. W. Cholesterol independent effect of LXR agonist TO-901317 on gamma-secretase. J. Neurochem., 2007, 101, 929-936. (Pubitemid 46683874)
124. Kukar, T. L.; Ladd, T. B.; Bann, M. A.; Fraering, P. C.; Narlawar, R.; Maharvi, G. M.; Healy, B.; Chapman, R.; Welzel, A. T.; Price, R. W.; Moore, B.; Rangachari, V.; Cusack, B.; Eriksen, J.; Jansen-West, K.; Verbeeck, C.; Yager, D.; Eckman, C.; Ye, W.; Sagi, S.; Cottrell, B. A.; Torpey, J.; Rosenberry, T. L.; Fauq, A.; Wolfe, M. S.; Schmidt, B.; Walsh, D. M.; Koo, E. H.; Golde, T. E. Substrate targeting γ-secretase modulators. Nature 2008, 453, 925-929.
125. Beher, D.; Clarke, E. E.; Wrigley, J. D.; Martin, A. C.; Nadin, A.; Churcher, I.; Shearman, M. S. Selected non-steroidal anti-inflammatory drugs and their derivatives target γ-secretase at a novel site-evidence for an allosteric mechanism. J. Biol. Chem., 2004, 279, 43419-43426 (Pubitemid 39390641)
126. Sato, T.; Tang, T.-C.; Reubins, G.; Fei, J. Z.; Fujimoto, T.; Kienlen-Campard, P.; Constantinescu, S. N.; Octave, J.-N; Aimoto, S.; Smith, S. O. A helix-to-coil transition at the s-cut site in the transmembrane dimer of the amyloid precursor protein is required for proteolysis. Proc. Natl. Acad. Sci. U. S. A., 2009, 106, 1421-1426.
127. Morihara, T.; Chu, T.; Ubeda, O.; Beech, W.; Cole, GM. Selective inhibition of Aβ42 production by NSAID R-enantiomers. J. Neurochem., 2002, 83, 1009-1012. (Pubitemid 35316052)
128. Kukar, T.; Prescott, S.; Eriksen, J. L.; Holloway, V.; Murphy, M. P.; Koo, E. H.; Golde, T. E.; Nicolle, M. M. Chronic administration of R-flurbiprofen attenuates learning impairments in transgenic amyloid precursor protein mice. BMC Neurosci., 2007, 8, 54.
129. 1-42 suppression by nonsteroidal anti-inflammatory drugs in young, plaque-free Tg2576 mice and in guinea pig neuronal cultures. J. Pharmacol. Exp. Ther, 2005, 312, 399-406. (Pubitemid 40096494)
130. Galasko, D. R.; Graff-Radford, N.; May, S.; Hendrix, S.; Cottrell, B. A.; Sagi, S. A.; Mather, G.; Laughlin, M.; Zavitz, K. H.; Swabb, E.; Golde, T. E.; Murphy, M. P. Koo, E. H. Safety, tolerability, pharmacokinetics, and Ab levels after short-term administration of R-flurbiprofen in healthy elderly individuals. Alzheimer. Dis. Assoc. Disord., 2007, 21, 292-299. (Pubitemid 350307433)
131. Wilcock, G. K.; Black, S. E.; Hendrix, S. B.; Zavitz, K. H.; Swabb, E. A.; Laughlin, M. A. Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial. Lancet Neurol, 2008, 7, 483-493.
132. Green, R. C.; Schneider, L. S.; Amato, D. A.; Beelen, A. P.; Wilcock, G.; Swabb, E. A.; Zavitz, K. H.; Tarenflurbil Phase 3 Study Group. Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. JAMA, 2009, 302, 2557-2564.
133. Wilcock, G. K.; Black, S. E.; Balch, A. H.; Amato, D. A.; Beelen, A. P.; Schneider, L. S.; Green, R. C.; Swabb, E. A.; Zavitz, K. H. Safety and efficacy of tarenflurbil in subjects with mild Alzheimer's disease: results from an 18-month international multi-center Phase 3 trial. Alzheimers Dement, 2009, 5(Suppl 1), P86 (Abstract O1-04-07).
134. Amino, H.; Hagiwara, H.; Murata, Y.; Watanabe, H.; Sasaki, T.; Miyagawa, T. E 2012: a novel γ-secretase modulator - mechanism of action. Alzheimers Dement., 2010;6(Suppl 1), S54-S542 (Abstract P3-307).
135. Hashimoto, T.; Ishibashi, A.; Hagiwara, H.; Murata, Y.; Takenaka, O.; Miyagawa, T. E2012: A novel γ-secretase modulator - pharmacology part. 13th International Conference on Alzheimer's Disease and Related Disorders (ICAD), Honolulu, July 10-15, 2010. Alzheimers Dement, 2010, 6(Suppl 1), S242 (Abstract P1-236).
136. Portelius, E.; Van Broeck, B.; Andreasson, U.; Gustavsson, M. K.; Mercken, M.; Zetterberg, H.; Borghys, H.; Blennow, K. Acute effect on the Aβ isoform pattern in CSF in response to γ-secretase modulator and inhibitor treatment in dogs. J. Alzheimers Dis., 2010, 21, 1005-1012.
137. Nagy, C.; Schuck, E.; Ishibashi, A.; Nakatani, Y.; Rege, B.; Lagovinsky, V. E 2012, a novel γ-secretase modulator, decreases plasma amyloid beta (AP) levels in humans. Alzheimers Dement. 2010, 6(Suppl 1), S574 (Abstract P3-415).
138. Imbimbo, B. P.; Del Giudice, E.; Colavito, D.; D'Arrigo, A.; Dalle Carbonare, M.; Villetti, G.; Facchinetti, F.; Volta, R., Pietrini, V.; Baroc, M. F.; Serneels, L.; De Strooper, B.; Leon, A. CHF5074, a novel γ-secretase modulator, reduces brain β-amyloid pathology in a transgenic mouse model of Alzheimer's disease without causing peripheral toxicity. J. Pharmacol. Exp. Ther., 2007, 323, 822-830.
139. Imbimbo, B. P.; Hutter-Paier, B.; Villetti, V.; Facchinetti, F.; Cenacchi, V.; Volta, R. Lanzillotta, A. Pizzi, M.; Windisch, M. CHF5074, a novel ysecretase modulator, attenuates brain β-amyloid pathology and learning deficit in a mouse model of Alzheimer's disease. Br. J. Pharmacol., 2009, 156, 982-993.
140. Imbimbo, B. P.; Giardino, L.; Sivilia, S.; Giuliani, A.; Gusciglio, M.; Pietrini, V; Del Giudice, E.; D'Arrigo, A.; Leon, A.; Villetti, G.; Calzà, C. CHF5074, a novel γ-secretase modulator, restores hippocampal neurogenesis potential and reverses contextual memory deficit in a transgenic mouse model of Alzheimer's disease. J. Alzheimers Dis., 2010, 20, 159-173.
141. Imbimbo, B. P.; Mackintosh, D.; Aponte, T.; Frigerio, E.; Breda, M.; Fernandez, M.; Giardino, L.; Calzà, L.; Norris, D.; Wagner, K.; Ross, J. Pharmacokinetics and pharmacodynamics of CHF5074, a novel γ-secretase modulator, after single oral administration to healthy male subjects. Alzheimers Dement, 2010, 6(Suppl 1), S573 (Abstract P3-411).
142. Imbimbo BP, Mackintosh D, Aponte T, Frigerio F, Breda M, Fernandez M, Giardino C., Calzà L, Norris D, Wagner K, Shenouda M. Safety and pharmacokinetics of CHF5074, a novel γ-secretase modulator, after multiple oral administrations to healthy humans. Alzheimers Dement, 2011;7(Suppl. 1), S457 (Abstract P2-466).
143. ClinicalTrial.gov Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074 and Exploration of Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment (CT04) [last accessed September 20, 2011: http://clinicaltrials.gov/ct2/show/NCT01303744? term=NCT01303744&rank=1].
144. ClinicalTrial.gov A Randomized, Double-blind, Placebo-controlled, Sequential Ascending, Single-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2212 in Healthy Subjects [last accessed September 20, 2011: http://clinicaltrials.gov/ct2/show/NCT01221259].
145. Felsenstein, K. M.; Spaulding, D.; Yang, Z.; Hodgon, H.; Costa, D.; Nolan, S.; Wen, M.; Lee, W.; Hrdlicka, L.; Catana, F.; Albaya, F.; Tu, Z.; Patzke, H.; Chesworth, R.; Shapiro, G.; Zaninovic, I.; Ahlijanian, M.; Koenig, G.; Rogers, K. Pharmacokinetic and pharmacodynamic analysis of the gammasecretase modulator (GSM) EVP-0015962. Alzheimers Dement, 2010, 6(Suppl 1), S538 (Abstract P3-295).
146. Rogers, K.; Leventhal, L.; Hopp, S.; Miller, M. J.; Yang, Z.; Hrdlicka, L.; Lee, W.; Hodgon, H.; Nolan, S.; Wen, M.; Koperniak, T.; Spaulding, D.; Catana, F.; Chesworth, R.; Shapiro, G.; Costa, D.; Ahlijanian, M.; Koenig, G.; Felsenstein, K.; The γ-secretase modulator EVP-0015962 improves cognitive deficits in Tg2576 mice concomitantly with decreases in Aβ42. Alzheimers Dement, 2010, 6(Suppl 1), Abstract P4-022.
147. Cheng, S.; Comer, D.; Mao, L.; Pleynet, D.; Yu, C.; Kounnas, M. Z.; Tyree, C.; Danks, A. D.; Wagner, S. L.; Comer, W. T. 2-Aminothiazoles derivatives as potent γ-secretase modulators. 240th ACS National Meeting, Boston, August 22-26, 2010, Abstract MEDI 1.
148. Minati, L.; Edginton, T.; Bruzzone, M. G.; Giaccone, G. Current concepts in Alzheimer's disease: a multidisciplinary review. Am. J. Alzheimers Dis. Other Demen., 2009, 24, 95-121.
149. Vellas, B.; Sol, O.; Snyder, P. J.; Ousset, P. J.; Haddad, R.; Maurin, M.; Lemarié, J. C.; Désiré, L.; Pando, M. P; EHT0202/002 study group. A 3-Month, randomized, placebo-controlled, double-blind study. Curr. Alzheimer Res. 2011, 8, 203-212.
150. Lannfelt, L.; Blennow, K.; Zetterberg, H.; Batsman, S.; Ames, D.; Harrison, J.; Masters, C. L.; Targum, S.; Bush, A. I.; Murdoch, R.; Wilson, J.; Ritchie, C. W.; PBT2-201-EURO study group. Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurol, 2008, 7, 779-786
151. Faux, N. G.; Ritchie, C. W.; Gunn, A.; Rembach, A.; Tsatsanis, A.; Bedo, J.; Harrison, J.; Lannfelt, L.; Blennow, K.; Zetterberg, H.; Ingelsson, M.; Masters, C. L.; Tanzi, R. E.; Cummings, J. L.; Herd, CM.; Bush, A. I. PBT2 rapidly improves cognition in Alzheimer's Disease: additional phase II analyses. J. Alzheimers Dis., 2010, 20, 509-516
152. Panza, F.; Frisardi, V.; Imbimbo, B. P.; Seripa, D.; Solfrizzi, V.; Pilotto, A. Monoclonal antibodies against β-amyloid (Ap) for the treatment of Alzheimer's disease: the Aβ target at a crossroads. Expert Opin. Biol. Ther., 2011, 11, 679-686.
153. Maillard, I.; Adler, S. H.; Pear, W. S. Notch and the immune system. Immunity, 2003, 19, 781-791. (Pubitemid 37542299)
154. Stanger, B. Z.; Datar, R.; Murtaugh, L. C.; Melton, D. A. Direct regulation of intestinal fate by Notch. Proc. Natl. Acad. Sci. U. S. A., 2005, 102, 12443-12448. (Pubitemid 41266378)
155. Panelos, J.; Massi, D. Emerging role of Notch signaling in epidermal differentiation and skin cancer. Cancer Biol Ther., 2009, 8, 1986-1993.
156. Searfoss, G. H.; Jordan, W. H.; Calligaro, D. O.; Galbreath, E. J.; Schirtzinger, L. M.; Berridge, B. R.; Gao, H.; Higgins, M. A.; May, P. C.; Ryan, T. P. Adipsin, a biomarker of gastrointestinal toxicity mediated by a functional γ-secretase inhibitor. J. Biol. Chem., 2003, 278, 46107-46116. (Pubitemid 37432761)
157. Lathia, J. D.; Mattson, M. P.; Cheng, A. Notch: from neural development to neurological disorders. J. Neurochem., 2008, 107, 1471-1481.
158. Costa, R. M.; Honjo, T.; Silva, A. J. Learning and memory deficits in Notch mutant mice. Curr. Biol. 2003, 13, 1348-1354. (Pubitemid 36953310)
159. Wang, Y.; Chan, S. L.; Miele, L.; Yao, P. J.; Mackes, J.; Ingram, D. K.; Mattson, M. P.; Furukawa, K. Involvement of Notch signaling in hippocampal synaptic plasticity. Proc. Natl. Acad. Sci. USA, 2004, 101, 9458-9462. (Pubitemid 38812896)
160. Xia, X.; Qian, S.; Soriano, S.; Wu, Y.; Fletcher, A. M.; Wang, X. J.; Koo, E. H.; Wu, X.; Zheng, H. Loss of presenilin 1 is associated with enhanced beta-catenin signaling and skin tumorigenesis. Proc. Natl. Acad. Sci. U. S. A., 2001, 98, 10863-10868 (Pubitemid 32878710)
161. He, G.; Luo, W.; Li, P.; Remmers, C.; Netzer, W. J.; Hendrick, J.; Bettayeb, K.; Flajolet, M.; Gorelick, F.; Wennogle, L. P.; Greengard, P. γ-Secretase activating protein is a therapeutic target for Alzheimer's disease. Nature, 2010, 467, 95-98.
162. Chen, F.; Hasegawa, H.; Schmitt-Ulms, G.; Kawarai, T.; Bohm, C.; Katayama, T.; Gu, Y.; Sanjo, N.; Glista, M.; Rogaeva, E.; Wakutani, Y.; Pardossi-Piquard, R.; Ruan, X.; Tandon, A.; Checler, F.; Marambaud, P.; Hansen, K.; Westaway, D.; St George-Hyslop, P.; Fraser P. TMP21 is a presenilin complex component that modulates γ-secretase but not ε-secretase activity. Nature, 2006, 440, 1208-1212.
163. Thathiah, A.; Spittaels, K.; Hoffmann, M.; Staes, M.; Cohen, A.; Horré, K.; Vanbrabant, M.; Coun, F.; Baekelandt, V.; Delacourte, A.; Fischer, D. F.; Pollet, D.; De Strooper, B.; Merchiers. P. The orphan G protein-coup led receptor 3 modulates amyloidp peptide generation in neurons. Science, 2009, 323, 946-951.
164. Checler. F.; Dunys, J.; Pardossi-Piquard, R.; Alves da Costa, C. p53 is regulated by and regulates members of the gamma-secretase complex. Neurodegener. Dis., 2010, 7, 50-55.
165. Goodger, Z. V.; Rajendran, L.; Trutzel, A.; Kohli, B. M.; Nitsch, R. M.; Konietzko, U. Nuclear signaling by the APP intracellular domain occurs predominantly through the amyloidogenic processing pathway. J. Cell Sci., 2009, 122, 3703-3714.
166. Müller, T.; Meyer, H. E.; Egensperger, R.; Marcus, K. The amyloid precursor protein intracellular domain (AICD) as modulator of gene expression, apoptosis, and cytoskeletal dynamics-relevance for Alzheimer's disease. Prog. Neurobiol, 2008, 85, 393-406.
167. Kim, J.; Onstead, L.; Randle, S.; Price, R.; Smithson, L.; Zwizinski, C.; Dickson, D. W.; Golde, T.; McGowan, E. Aβ40 inhibits amyloid deposition in vivo. J. Neurosci., 2007, 27, 627-633. (Pubitemid 46143766)
168. Wrigley, J. D. J.; Martin, A. C. L.; Clarke, E. E.; Lewis, H. D.; Pollack, S. J.; Shearman, M. S.; Beher, D. Modulation versus inhibition - selected NSAIDs can act as γ-secretase inhibitors in vitro. 33rd Annual Meeting of Society of Neuroscience. New Orleans, November 8-12, 2003. Abstract 295.2.
169. Terrando, N.; Monaco, C.; Ma, D.; Foxwell, B. M.; Feldmann, M.; Maze, M. Tumor necrosis factor-α triggers a cytokine cascade yielding postoperative cognitive decline. Proc. Natl. Acad. Sci. U. S. A., 2010, 107, 20518-20522.
170. Wilkinson, B. L.; Cramer, P. E.; Varvel, N. H.; Reed-Geaghan, E.; Jiang, Q.; Szabo, A.; Herrup, K.; Lamb, B. T.; Landreth, G. E. Ibuprofen attenuates oxidative damage through NOX2 inhibition in Alzheimer's disease. Neurobiol. Aging., 2010, Aug. 7. [Epub ahead of print].
171. Varvel, N. H.; Bhaskar, K.; Kounnas, M. Z.; Wagner, S. L.; Yang, Y.; Lamb, B. T.; Herrup, K. NSAIDs prevent, but do not reverse, neuronal cell cycle reentry in a mouse model of Alzheimer disease. J. Clin. Invest., 2009, 119, 3692-3702.
172. Zhao, X.; Rebeck, G. W.; Hoe, H. S.; Andrews, P. M. Tarenflurbil protection from cytotoxicity is associated with an upregulation of neurotrophins. J. Alzheimers Dis., 2008;15:397-407.
173. 2+ overload underlies Abeta oligomers neurotoxicity providing an unexpected mechanism of neuroprotection by NSAIDs. PLoS One, 2008, 3, e2718.
174. Lichtenstein, M.; Carriba, P.; Wojciak-Stothard, B.; Baltrons, M. A.; Petersen, J.; García, A.; Galea, E. Secretase-independent and RhoGTPase/ERK/PAK regulation of cytoskeleton dynamics and motility in astrocytes by NSAIDs and derivatives. J. Alzheimers Dis., 2010, 22, 1135-1155.
175. Holmes, C.; Boche, D.; Wilkinson, D.; Yadegarfar, G.; Hopkins, V.; Bayer, A.; Jones, R. W.; Bullock, R.; Love, S.; Neal, J. W.; Zotova, E.; Nicoll, J. A. Long-term effects of Aβ42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet, 2008, 372, 216-223. (Pubitemid 351978111)
176. Castellani, R. J.; Lee, H. G.; Zhu, X.; Perry, G.; Smith, M. A. Alzheimer disease pathology as a host response. J. Neuropathol. Exp. Neurol, 2008, 67, 523-531. (Pubitemid 351787079)
177. Castellani, R. J.; Lee, H. G.; Siedlak, S. L.; Nunomura, A.; Hayashi, T.; Nakamura, M.; Zhu, X.; Perry, G.; Smith, M. A. Reexamining Alzheimer's disease: evidence for a protective role for amyloid-beta protein precursor and amyloid-beta. J. Alzheimers Dis., 2009, 18, 447-452.
178. Tampellini, D.; Rahman, N.; Gallo, E. F.; Huang, Z.; Dumont, M.; Capetillo-Zarate, E.; Ma, T.; Zheng, R.; Lu, B.; Nanus, D. M.; Lin, M. T.; Gouras, G. K. Synaptic activity reduces intraneuronal Aβ, promotes APP transport to synapses, and protects against Aβ related synaptic alterations. J. Neurosci. 2009, 29, 9704-9713.
179. Abramov, E.; Dolev, I.; Fogel, H.; Ciccotosto, G. D.; Ruff, E.; Slutsky, I. Amyloid-β as a positive endogenous regulator of release probability at hippocampal synapses. Nature Neurosci., 2009, 12, 1567-1576.
180. Puzzo, D.; Privitera, L.; Leznik, E.; Fà, M.; Staniszewski, A.; Palmeri, A.; Arancio, O. Picomolar amyloid-P positively modulates synaptic plasticity and memory in hippocampus. J. Neurosci. 2008, 28, 14537-14545.
181. Morley, J. E.; Farr, S. A.; Banks, W. A.; Johnson, S. N.; Yamada, K. A.; Xu, L. A physiological role for amyloid-P protein: enhancement of learning and memory. J Alzheimers Dis, 2010, 19, 441-449.
182. Bennett, D. A.; Schneider, J. A.; Arvanitakis, Z.; Kelly, J. F.; Aggarwal, N. T.; Shah, R. C.; Wilson, R. S. Neuropathology of older persons without cognitive impairment from two community based studies. Neurology, 2006, 66, 1837-1844. (Pubitemid 44049813)
183. Aizenstein, H. J.; Nebes, R. D.; Saxton, J. A.; Price, J. C.; Mathis, C. A.; Tsopelas, N. D.; Ziolko, S. K.; James, J. A.; Snitz, B. E.; Houck, P. R.; Bi, W.; Cohen, A. D.; Lopresti, B. J.; DeKosky, S. T.; Halligan, E. M.; Klunk, W. E. Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch. Neurol, 2008, 65, 1509-1517.
184. Struble, R. G.; Ala, T.; Patrylo, P. R.; Brewer, G. J., Yan, X. X. Is brain amyloid production a cause or a result of dementia of the Alzheimer's type? J. Alzheimers Dis., 2010, 22, 393-399.
185. Vossel, K. A.; Zhang, K.; Brodbeck, J.; Daub, A. C.; Sharma, P.; Finkbeiner, S.; Cui, B.; Mucke, L. Tau reduction prevents AP-induced defects in axonal transport. Science, 2010, 330, 198.
186. Duce, J. A.; Tsatsanis, A.; Cater, M. A.; James, S. A.; Robb, E.; Wikhe, K.; Leong, S. L.; Perez, K.; Johanssen, T.; Greenough, M. A.; Cho, H. H.; Galatis, D.; Moir, R. D.; Masters, C. L.; McLean, C.; Tanzi, R. E.; Cappai, R.; Barnham, K. J.; Ciccotosto, G. D.; Rogers, J. T.; Bush, A. I. Iron-export ferroxidase activity of β-amyloid precursor protein is inhibited by zinc in Alzheimer's disease. Cell, 2010, 142, 857-867.
187. Dubois, B.; Feldman, H. H.; Jacova, C.; Cummings, J. L.; Dekosky, S. T.; Barberger-Gateau, P.; Delacourte, A.; Frisoni, G.; Fox, N. C.; Galasko, D.; Gauthier, S.; Hampel, H.; Jicha, G. A.; Meguro, K.; O'Brien, J.; Pasquier, F.; Robert, P.; Rossor, M.; Salloway, S.; Sarazin, M.; de Souza, L. C.; Stern, Y.; Visser, P. J.; Scheltens, P. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007, 6, 734-746. (Pubitemid 47058377)
188. Dubois, B.; Feldman, H. H.; Jacova, C.; Dekosky, S. T.; Barberger-Gateau, P.; Cummings, J.; Delacourte, A.; Galasko, D.; Gauthier, S.; Jicha, G.; Meguro, K.; O'Brien, J.; Pasquier, F.; Robert, P.; Rossor, M.; Salloway, S., Stern, Y, Visser, P. J., Scheltens, P. Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol. 2011, 9, 1118-1127.
189. McKhann, G. M.; Knopman, D. S.; Chertkow, H.; Hyman, B. T.; Jack, C. R. Jr.; Kawas, C. H.; Klunk, W. E.; Koroshetz, W. J.; Manly, J. J.; Mayeux, R.; Mohs, R. C.; Morris, J. C.; Rossor, M. N.; Scheltens, P.; Carrillo, M. C.; Thies, B.; Weintraub, S.; Phelps, C. H. The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011, 7, 263-269.
190. Albert, M. S.; DeKosky, S. T.; Dickson, D.; Dubois, B.; Feldman, H. H.; Fox, N. C.; Gamst, A.; Holtzman, D. M.; Jagust, W. J.; Petersen, R. C.; Snyder, P. J.; Carrillo, M. C.; Thies, B.; Phelps, C. H. The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011, 7, 270-279.
191. Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R. Jr., Kaye, J., Montine, T. J., Park, D. C., Reiman, E. M., Rowe, C. C., Siemers, E., Stern, Y., Yaffe, K., Carrillo, M. C., Thies, B., Morrison-Bogorad, M., Wagster, M. V., Phelps, C. H. Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011, 7, 280-292.
192. Weiner, M. W.; Aisen, P. S.; Jack, C. R. Jr.; Jagust, W. J.; Trojanowski, J. Q.; Shaw, L.; Saykin, A. J.; Morris, J. C.; Cairns, N.; Beckett, L. A.; Toga, A.; Green, R.; Walter, S.; Soares, H.; Snyder, P.; Siemers, E.; Potter, W.; Cole, P. E., Schmidt, M.; Alzheimer's Disease Neuroimaging Initiative. The Alzheimer's disease neuroimaging initiative: progress report and future plans. Alzheimers Dement. 2010, 6, 202-211.